 |
인쇄하기
취소
|
Hanall to conduct phase 2 trial for protein therapeutic in US
Hanall BioPharma says it has filed its phase 2 application for its lead protein product, Hanferon (interferon alpha), to the U.S. Food and Drug Administration.
If approved, the company will conduct phase 2 trial in hepatitis C patients in the U.S. from October this year.
In the pipeline of modified protein therapeutic molecules, called Resistein-technology, include Hanferon, HanTropin (hG...
If approved, the company will conduct phase 2 trial in hepatitis C patients in the U.S. from October this year.
In the pipeline of modified protein therapeutic molecules, called Resistein-technology, include Hanferon, HanTropin (hG...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.